

2021-2022 BOARD OF DIRECTORS

President Daniel P. McQuillen, M.D., FIDSA Beth Israel Lahey Health Lahey Hospital & Medical Center Burungton, MA

President-Elect Carlos Del Rio, M.D., FIDSA EMORY SCHOOL OF MEDICINE AT GRADY HEALTH SYSTEM ATLANTA, GA

Vice President Steven K. Schmitt, M.D., FIDSA CLEVELAND CLINIC CLEVELAND, OH

Secretary Angela M. Caliendo, M.D., Ph.D., FIDSA Aupert Medical School of Brown University Rhode Island Hospital Providence, RI

Treasurer Jeanne Marrazzo, M.D., MPH, FIDSA University of Alabama at Brimingham School of Medicine Birmingham, AL

Immediate Past President Barbara D. Alexander, M.D., MHS, FIDSA Duke University Durham, NC

Lilian M. Abbo, M.D., FIDSA University of Mami Miller School of Mediane Miami, FL

Adaora A. Adimora, M.D., MPH, FIDSA UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE CHAPEL HILL NC

Cesar A. Arias, M.D., Ph.D., FIDSA Houston Methodist Hospital Houston, TX

Wendy Armstrong, M.D., FIDSA EMORY UNIVERSITY ATLANTA, GA

Maximo O. Brito, M.D., MPH, FIDSA UNIVERSITY OF ILLINOIS AT CHICAGO CHICAGO, IL

Rana Chakraborty, M.D., MSc, D.Phil., FIDSA Mayo Clinic Rochester, MN

Kimberly E. Hanson, M.D., FIDSA University of Utah Salt Lake City, UT

John B. Lynch, III, M.D., MPH, FIDSA Harborview Medical Center University of Washington Seattle, WA

Jasmine R. Marcelin, M.D., FIDSA UNIVERSITY OF NEBRASKA MEDICAL CENTER OMAHA, NE

Chief Executive Officer Christopher D. Busky, CAE

IDSA Headquarters

4040 Wilson Boulevard Suite 300 Arlington, VA 22203 TEL: (703) 299-0200 FAX: (703) 299-0204 EMAIL ADDRESS: info@idsociety.org WEBSITE: WWW.idsociety.org



July 12, 2021

The Honorable Rosa DeLauro Chair Committee on Appropriations United States House of Representatives Washington, DC 20515

The Honorable Tom Cole Ranking Member LHHS Subcommittee Committee on Appropriations United States House of Representatives Washington, DC 20515

The Honorable Harold Rogers Ranking Member Subcommittee on State and Foreign Operations Committee on Appropriations United States House of Representatives Washington, DC 20515

The Honorable Kay Granger Ranking Member Committee on Appropriations United States House of Representatives Washington, DC 20515

The Honorable Barbara Lee Chairwoman Subcommittee on State and Foreign Operations Committee on Appropriations United States House of Representatives Washington, DC 20515

Subject: Infectious Diseases Programs in FY2023 Appropriations Bills

Dear Chairwoman DeLauro, Ranking Member Granger, Ranking Member Cole, Chairwoman Lee, and Ranking Member Rogers,

On behalf of the Infectious Diseases Society of America (IDSA) and our 12,000 members, thank you for your leadership in providing increased FY2023 funding in the Labor, Health, and Human Services (LHHS) and State and Foreign Operations (SFOPs) appropriations bills for domestic and global infectious diseases (ID) programs necessary to protect public health; prevent, prepare for and respond to outbreaks and other emergencies; spur biomedical research; and support early career ID scientists. We particularly appreciate the increased investments in the federal response to antimicrobial resistance (AMR).

IDSA members care for patients with serious infections, including influenza, HIV/AIDS, tuberculosis, viral hepatitis, infections associated with opioid use, infections associated with cancer and transplantation, as well as infections that are resistant to available antimicrobials. We are on the frontlines of the COVID-19 pandemic and monkeypox outbreak.

Increased AMR funding in the House Appropriations mark is critical to increase AMR surveillance and prevention, improve antimicrobial stewardship, expand AMR research and

strengthen the antibiotic pipeline. Key investments include \$202 million for the Antibiotic Resistance Solutions Initiative at the Centers for Disease Control and Prevention, \$845 million in overall funding for the Biomedical Advance Research and Development Authority, including a \$100 million increase to spur antibiotic research and development, and \$6.642 billion for the National Institute of Allergy and Infectious Diseases, including \$560 million for AMR research. Additionally, we appreciate increased funding for other vital domestic and global ID programs., including those listed below:

Thank you for the attention given to infectious diseases in the House FY2023 appropriations bills passed by the full committee. We look forward to working with you to realize increased investments to combat infectious diseases, especially AMR, by passing a final FY2023 appropriations bill. If we can serve as a resource for your efforts, please have your staff contact Lisa Cox, IDSA Director of Government Relations, at <u>lcox@idsociety.org</u>.

Sincerely,

Daniel P. McQuillen, MD, FIDSA President, Infectious Diseases Society of America

Labor, Health and Human Services Appropriations Bill

- \$31 million in funding for the National Healthcare Safety Network at CDC, a \$10 million increase over FY 2022
- \$50 million in funding for the **Advanced Molecular Detection initiative at CDC**, a \$15 million increase over FY 2022
- \$825 million for CDC's Immunization Program, a \$175 million increase over FY 2022
- \$65 million for CDC's Quarantine Program, a \$15 million increase over FY 2022
- \$43 million for infectious diseases and opioid activities at CDC, \$25 million increase over FY 2022
- \$1.463 billion in funding for the **Division of HIV**, **Viral Hepatitis, Sexually Transmitted Diseases and Tuberculosis**, a \$118 million increase over FY 2022
- \$757 million, an increase of \$111 million above FY 2022, for the **Center for Global Health**, which includes \$353 million for global health security, a \$100 million increase
- \$99 million to NIH's John C. Fogarty International Center, \$12 million over FY 2022 funding
- \$250 million, an increase of \$150 million above FY 2022, to modernize public health data surveillance and analytics at CDC and state and local health departments

State and Foreign Operations Appropriations Bill

- \$1 billion for global health security, an increase of \$300 million, to prevent future pandemics through both bilateral and multilateral mechanisms
- \$2 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria, a \$440 million increase to support a strong U.S. commitment to the seventh replenishment of the Global Fund in support of the goal of ending the epidemics of AIDS, TB and malaria
- \$4.395 billion for the President's Emergency Plan for AIDS Relief, a \$5 million increase
- \$469 million for the USAID global TB program, an increase of almost \$100 million over FY 2022 funding